1.61
price down icon2.42%   -0.04
after-market アフターアワーズ: 1.61
loading
前日終値:
$1.65
開ける:
$1.65
24時間の取引高:
2.05M
Relative Volume:
0.96
時価総額:
$716.38M
収益:
$69.64M
当期純損益:
$-26.09M
株価収益率:
-22.52
EPS:
-0.0715
ネットキャッシュフロー:
$-38.80M
1週間 パフォーマンス:
-8.00%
1か月 パフォーマンス:
-19.50%
6か月 パフォーマンス:
-5.85%
1年 パフォーマンス:
+11.81%
1日の値動き範囲:
Value
$1.59
$1.655
1週間の範囲:
Value
$1.59
$1.78
52週間の値動き範囲:
Value
$1.10
$2.68

Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile

Name
名前
Lexicon Pharmaceuticals Inc
Name
セクター
Healthcare (1051)
Name
電話
(281) 863-3000
Name
住所
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Name
職員
81
Name
Twitter
@LexPharma
Name
次回の収益日
2026-11-05
Name
最新のSEC提出書
Name
LXRX's Discussions on Twitter

Compare LXRX vs VRTX, MRNA, REGN, ARGX, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
LXRX icon
LXRX
Lexicon Pharmaceuticals Inc
1.61 716.38M 69.64M -26.09M -38.80M -0.0715
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
485.22 122.98B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
216.25 86.33B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
753.12 77.54B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
802.64 50.47B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
188.44 40.39B 742.00K -1.37B -1.07B -7.0731

Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-09-28 開始されました Cantor Fitzgerald Overweight
2025-03-05 ダウングレード Leerink Partners Outperform → Market Perform
2024-06-17 開始されました H.C. Wainwright Buy
2024-04-30 開始されました Leerink Partners Outperform
2023-03-07 開始されました Jefferies Hold
2022-08-12 開始されました Piper Sandler Overweight
2021-01-29 アップグレード JP Morgan Underweight → Neutral
2021-01-29 ダウングレード Wedbush Outperform → Neutral
2020-12-08 アップグレード Citigroup Neutral → Buy
2020-11-18 アップグレード Gabelli & Co Hold → Buy
2019-12-11 ダウングレード Gabelli & Co Buy → Hold
2019-11-08 ダウングレード Citigroup Buy → Neutral
2019-09-11 アップグレード Gabelli & Co Hold → Buy
2019-07-29 ダウングレード Stifel Buy → Hold
2019-03-25 アップグレード Gabelli & Co Sell → Hold
2018-07-31 繰り返されました Stifel Buy
2018-02-23 ダウングレード Needham Buy → Hold
2018-02-14 ダウングレード JP Morgan Neutral → Underweight
2017-03-01 繰り返されました H.C. Wainwright Buy
2017-03-01 繰り返されました Wedbush Outperform
2016-10-07 開始されました H.C. Wainwright Buy
2016-08-05 繰り返されました Wedbush Outperform
2016-08-02 開始されました Citigroup Buy
2016-03-02 繰り返されました Wedbush Outperform
2015-11-09 繰り返されました Wedbush Outperform
2015-09-28 アップグレード Gabelli & Co Sell → Hold
2015-09-18 ダウングレード Gabelli & Co Hold → Sell
2015-08-10 ダウングレード JP Morgan Overweight → Neutral
すべてを表示

Lexicon Pharmaceuticals Inc (LXRX) 最新ニュース

pulisher
Oct 09, 2026

Lexicon Pharmaceuticals (LXRX) Short Interest & Short Float | Updated Oct 2026 $LXRX - MarketBeat

Oct 09, 2026
pulisher
Oct 06, 2026

Lexicon Pharmaceuticals stock faces a Q2 loss as trials advance - AD HOC NEWS

Oct 06, 2026
pulisher
Oct 06, 2026

Lexicon Pharmaceuticals, Inc.Common Stock (Nasdaq:LXRX) Stock Quote - FinancialContent

Oct 06, 2026
pulisher
Oct 06, 2026

Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript - Benzinga

Oct 06, 2026
pulisher
Oct 06, 2026

Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript - Benzinga

Oct 06, 2026
pulisher
Oct 04, 2026

Fair value rises to USD 4.55 for Lexicon Pharmaceuticals stock - AD HOC NEWS

Oct 04, 2026
pulisher
Oct 03, 2026

Lexicon Pharmaceuticals, Inc. (LXRX) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 03, 2026
pulisher
Oct 02, 2026

Lexicon Pharmaceuticals (LXRX) Stock Fair Value Rises After SONATA HCM Trial Progress - Yahoo Finance

Oct 02, 2026
pulisher
Oct 01, 2026

Cantor Fitzgerald targets Lexicon Pharmaceuticals stock at USD 8.00 - AD HOC NEWS

Oct 01, 2026
pulisher
Sep 30, 2026

Lexicon Pharmaceuticals upgraded to Buy with ke... - Pluang

Sep 30, 2026
pulisher
Sep 30, 2026

Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More - Seeking Alpha

Sep 30, 2026
pulisher
Sep 28, 2026

Analyst Bullish on Lexicon Pharmaceuticals' Prospects - Intellectia AI

Sep 28, 2026
pulisher
Sep 28, 2026

Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today - Yahoo Finance

Sep 28, 2026
pulisher
Sep 28, 2026

Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today - The Motley Fool

Sep 28, 2026
pulisher
Sep 28, 2026

Cantor Fitzgerald Initiates Overweight on Lexicon Pharmaceuticals (LXRX) Ahead of Phase 3 Inpefa Data - GuruFocus

Sep 28, 2026
pulisher
Sep 28, 2026

Lexicon a new overweight at Cantor on optimism for Inpefa in cardiomyopathy - Seeking Alpha

Sep 28, 2026
pulisher
Sep 28, 2026

Why is Lexicon Pharmaceuticals stock surging today? By Investing.com - Investing.com Canada

Sep 28, 2026
pulisher
Sep 28, 2026

Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM - Investing.com

Sep 28, 2026
pulisher
Sep 28, 2026

This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Sep 28, 2026
pulisher
Sep 28, 2026

LXRX Initiated Coverage by Cantor Fitzgerald -- Rating Set at Ov - GuruFocus

Sep 28, 2026
pulisher
Sep 28, 2026

Cantor Fitzgerald initiates coverage of Lexicon Pharmaceuticals with Overweight rating, $8 price target - TradingView

Sep 28, 2026
pulisher
Sep 28, 2026

Lexicon Pharmaceuticals (NasdaqCM:LXRX) Stock Forecast & Analyst Predictions - Simply Wall Street

Sep 28, 2026
pulisher
Sep 28, 2026

Lexicon Pharmaceuticals Shares Rise After Cantor Fitzgerald Initiates With Overweight Rating - Yahoo Finance

Sep 28, 2026
pulisher
Sep 28, 2026

Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM - Yahoo Finance

Sep 28, 2026
pulisher
Sep 23, 2026

Lexicon Pharmaceuticals stock trades near its yearly low - AD HOC NEWS

Sep 23, 2026
pulisher
Sep 20, 2026

Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data - finance.yahoo.com

Sep 20, 2026
pulisher
Sep 10, 2026

Lexicon Pharmaceuticals at cantorfitzgerald healthcare conference: focus sharpens - Investing.com

Sep 10, 2026
pulisher
Sep 10, 2026

Lexicon Pharmaceuticals at cantorfitzgerald healthcare conference: focus sharpens By Investing.com - Investing.com Canada

Sep 10, 2026
pulisher
Sep 09, 2026

Lexicon Pharmaceuticals at Citi summit: hcm data, t1d reset By Investing.com - Investing.com Canada

Sep 09, 2026
pulisher
Sep 09, 2026

Lexicon Pharmaceuticals at Citi summit: hcm data, t1d reset By Investing.com - Investing.com UK

Sep 09, 2026
pulisher
Sep 09, 2026

Heart Failure Trial Data Might Change The Case For Investing In Lexicon Pharmaceuticals (LXRX) - webull.com

Sep 09, 2026
pulisher
Sep 08, 2026

Heart Failure Trial Data Might Change The Case For Investing In Lexicon Pharmaceuticals (LXRX) - simplywall.st

Sep 08, 2026
pulisher
Sep 05, 2026

Lexicon Pharmaceuticals Stock Price Forecast. Should You Buy LXRX? - StockInvest.us

Sep 05, 2026
pulisher
Sep 04, 2026

Here's Why You Should Add LXRX Stock to Your Portfolio Now - Eastern Progress

Sep 04, 2026
pulisher
Sep 04, 2026

Lexicon Pharmaceuticals Inc (LXRX) Valuation: PE, PB & Fair Value Analysis - TradingKey

Sep 04, 2026
pulisher
Sep 01, 2026

Three New York investor conferences will hear from Lexicon - Stock Titan

Sep 01, 2026
pulisher
Sep 01, 2026

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences - finance.yahoo.com

Sep 01, 2026
pulisher
Aug 31, 2026

Lexicon Pharmaceuticals (LXRX) Posts Positive Heart Failure Tria - GuruFocus

Aug 31, 2026
pulisher
Aug 31, 2026

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure - Yahoo Finance

Aug 31, 2026
pulisher
Aug 31, 2026

Sotagliflozin Linked to Fewer Heart-Failure Events in Patients With BP as Low as 100 - Stock Titan

Aug 31, 2026
pulisher
Aug 27, 2026

Lexicon Pharmaceuticals Inc. (LXRX) Key Financial Ratios – Valuation, Profitability & More - Value Research

Aug 27, 2026
pulisher
Aug 24, 2026

Lexicon (LXRX) Results at a Glance: EPS Misses Its Estimate in the Reported Period; Post-Earnings: The Market Price Advances 0.87% at the CloseNegative Surprise Momentum - vinanet.vn

Aug 24, 2026
pulisher
Aug 24, 2026

Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk - marketscreener.com

Aug 24, 2026
pulisher
Aug 24, 2026

Lexicon Pharmaceuticals (LXRX) Advances Obesity Drug Trial, Faces Valuation Challenges - GuruFocus

Aug 24, 2026
pulisher
Aug 24, 2026

Lexicon Pharmaceuticals Gets $10 Million Novo Nordisk Milestone Payment for LX9851 - marketscreener.com

Aug 24, 2026
pulisher
Aug 24, 2026

LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon - Yahoo Finance

Aug 24, 2026
pulisher
Aug 24, 2026

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851 - finance.yahoo.com

Aug 24, 2026
pulisher
Aug 20, 2026

The Bull Case For Lexicon Pharmaceuticals (LXRX) Could Change Following Steep Q2 Revenue Drop And Loss Shift - simplywall.st

Aug 20, 2026
pulisher
Aug 20, 2026

The Bull Case For Lexicon Pharmaceuticals (LXRX) Could Change Following Steep Q2 Revenue Drop And Loss Shift - simplywall.st

Aug 20, 2026
pulisher
Aug 19, 2026

Lexicon (LXRX) Levels: Slides 0.41% to $2.41 in the Current Update; Technical Setup - vinanet.vn

Aug 19, 2026

Lexicon Pharmaceuticals Inc (LXRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Lexicon Pharmaceuticals Inc (LXRX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Sullivan Diane E.
Director
Jun 03 '26
Option Exercise
0.00
89,312
0
126,122
SOBECKI CHRISTOPHER J
Director
Jun 03 '26
Option Exercise
0.00
89,312
0
293,177
Cheung Ivan
Director
Jun 03 '26
Option Exercise
0.00
89,312
0
89,312
BARKER SAM L
Director
Jun 03 '26
Option Exercise
0.00
89,312
0
213,771
Amouyal Philippe
Director
Jun 03 '26
Option Exercise
0.00
89,312
0
374,486
DEBBANE RAYMOND
Director
Jun 03 '26
Option Exercise
0.00
89,312
0
1,995,498
Artal Participations S.a r.l.
Director
Apr 30 '26
Option Exercise
0.00
20,421,735
0
175,156,062
DEBBANE RAYMOND
Director
Feb 25 '26
Buy
1.49
2,000
2,980
1,906,186
DEBBANE RAYMOND
Director
Feb 23 '26
Buy
1.47
100,000
147,000
1,904,186
DEBBANE RAYMOND
Director
Feb 20 '26
Buy
1.48
100,000
147,790
1,804,186
$8.69
price down icon 6.05%
$6.71
price down icon 2.26%
$2.41
price down icon 8.02%
$7.00
price down icon 0.85%
$9.27
price down icon 5.21%
$3.83
price down icon 3.28%
大文字化:     |  ボリューム (24 時間):